Director at Avalo Therapeutics (AVTX) granted 20,100 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Avalo Therapeutics director Kevin Robert Lind received a stock option grant covering 20,100 shares of Common Stock. The option has an exercise price of $13.96 per share and expires on June 2, 2036. It vests 100% on the first anniversary of the grant date, subject to his continued board service. Following this award, he holds 20,100 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lind Kevin Robert

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,100	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 20,100 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option shares granted: 20,100 shares Exercise price: $13.96 per share Expiration date: June 2, 2036 +1 more

4 metrics

Option shares granted 20,100 shares Stock Option (Right to Buy) granted to director

Exercise price $13.96 per share Conversion or exercise price of stock option

Expiration date June 2, 2036 Option expiration for director grant

Total derivative holdings after grant 20,100 options Total shares following transaction

Key Terms

Stock Option (Right to Buy), exercise price, vests 100% on the first anniversary, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 13.9600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests 100% on the first anniversary financial

"The stock option vests 100% on the first anniversary of the date of grant"

expiration date financial

"expiration_date: 2036-06-02T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/04/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lind Kevin Robert

(Last)

(First)

(Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$13.96	06/02/2026		A		20,100		⁽¹⁾	06/02/2036	Common Stock	20,100	$0	20,100	D

Explanation of Responses:

1. The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Avalo Therapeutics (AVTX) director Kevin Robert Lind report on this Form 4?

Kevin Robert Lind reported receiving a stock option grant for 20,100 shares of Avalo Therapeutics Common Stock. The award is compensation, not an open-market trade, and gives him the right to buy shares at a fixed exercise price in the future.

How many Avalo Therapeutics shares are covered by Kevin Robert Lind’s new stock option?

The new stock option covers 20,100 shares of Avalo Therapeutics Common Stock. This represents the full amount granted in this Form 4 and matches his total derivative holdings following the transaction reported in the filing.

What is the exercise price of Kevin Robert Lind’s Avalo Therapeutics stock option?

The exercise price of the stock option granted to Kevin Robert Lind is $13.96 per share. This price is the fixed cost at which he can purchase Avalo Therapeutics Common Stock if he chooses to exercise the option in the future.

When does Kevin Robert Lind’s Avalo Therapeutics stock option vest and become exercisable?

The stock option vests 100% on the first anniversary of the grant date. Vesting is conditioned on Lind’s continued service as a director on that vesting date, meaning he must remain on the board for the option to fully vest.

What is the expiration date of Kevin Robert Lind’s Avalo Therapeutics stock option?

The stock option issued to Kevin Robert Lind expires on June 2, 2036. After this expiration date, he will no longer have the right to exercise the option to purchase Avalo Therapeutics Common Stock at the stated exercise price.

Does this Avalo Therapeutics Form 4 show any stock bought or sold on the market?

This Form 4 shows a grant of a stock option, not an open-market purchase or sale. The transaction is classified as a grant or award acquisition, reflecting equity compensation rather than a discretionary trade in Avalo Therapeutics shares.